Bayer's Legal Landscape Shows Signs of Stabilization

Bayer gains ground in U.S. glyphosate litigation with new state laws and settlements, but faces a pivotal Supreme Court hearing and constrained 2026 cash flow due to legal costs.

Bayer is making significant headway in managing its substantial legal liabilities in the United States. While strategic developments in legislation and pharmaceutical regulation aim to alleviate the immense pressure of recent years, the company's financial outlook for 2026 remains constrained.

Regulatory and Legal Milestones Provide Relief

A key development emerged from Kentucky, where a new statute took effect on April 2. This law establishes a legal shield for manufacturers of agricultural chemicals, significantly impeding state-level lawsuits alleging inadequate risk warnings, provided the product labeling complies with federal standards. By following precedents set by North Dakota and Georgia, this move incrementally strengthens Bayer's position in ongoing glyphosate-related litigation.

In a parallel legal maneuver, a settlement reached in Florida last Friday has averted an initial local trial. The conglomerate continues to pursue final court approval for a comprehensive nationwide settlement valued at $7.25 billion. This agreement is designed to resolve approximately 200,000 existing and future claims, with associated payments structured to be disbursed over a period extending up to 21 years.

A Pivotal Supreme Court Date and Pharmaceutical Advances

The most consequential legal decision is anticipated on April 27, 2026, when the U.S. Supreme Court is scheduled to hear arguments. Bayer's central contention is that federal law preempts more stringent state-level labeling requirements. A ruling expected in June could fundamentally redefine the company's future liability risk assessment.

Away from the courtroom, Bayer has secured favorable regulatory decisions from the U.S. Food and Drug Administration (FDA). The label for Eylea HD has been updated, allowing patients who respond well in the first year to reduce injection frequency to once every 20 weeks. This extended treatment cycle enhances the drug's competitive market stance. Furthermore, an FDA decision regarding a new pre-filled syringe for the medication is pending this April.

Financial Strain Persists Amid Progress

Despite these operational and legal advances, Bayer's financial projections for 2026 are burdened. The company anticipates a negative free cash flow, partly due to an estimated €5 billion in litigation-related expenditures. Adjusted EBITDA is forecast to be in the range of €9.1 to €9.6 billion. The company's shares closed trading on Friday at $11.26, representing a year-to-date gain of 1.53%.

Shareholders should note April 28, 2026, as a key date, marking the ex-dividend day for a planned distribution of €0.11 per share.